PCa-Specific Survival Probabilities (%) in Patients With Pathologic 11C-Choline Uptake and in Patients Without (M0) and With (M1) Distant Metastases
| PET/CT positive | ||||
| Survival (y) | Prostatic bed/lymph nodes (n = 63)* | Skeleton (n = 49) | M0, prostatic bed/pelvic lymph nodes (n = 46)† | M1, retroperitoneal lymph nodes/skeleton (n = 66)† |
| 5 | 92.6% (89.3%–95.9%) | 65.9% (59.0%–72.8%) | 97.8% (95.6%–1.00%) | 69.6% (63.9%–75.3%) |
| 10 | 61.2% (54.1%–68.3%) | 47.1% (39.0%–55.2%) | 75.5% (68.1%–82.9%) | 55.0% (47.9%–62.1%) |
| 15 | 20.4% (10.2%–30.6%) | 5.6% (0.3%–10.9%) | 25.0% (12.5%–37.5%) | 4.7% (0.2%–9.2%) |